Document:

Amended and Restated Investor Rights Agreement

 Exhibit 4.9 
 ADVANCED BIOHEALING, INC. 
  

 
 AMENDED AND
RESTATED 
 INVESTOR RIGHTS AGREEMENT 
  

 
 Dated as of
February 23, 2007 

 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”), dated as of February 23, 2007, by and
among Advanced BioHealing, Inc., a Delaware corporation (the “Company”), the holders of the Company’s Series C Preferred Stock, $.001 par value per share (the “Series C Preferred Stock”) set forth
on Exhibit A attached hereto, the holders of the Company’s Series C-1 Preferred Stock, $.001 par value per share (the “Series C-1 Preferred Stock”) set forth on Exhibit A attached hereto, the holders of
shares of the Company’s Series B Preferred Stock, $.001 par value per share (the “Series B Preferred Stock”) set forth on Exhibit A attached hereto (such holders of Series C Preferred Stock, Series C-1 Preferred
Stock and Series B Preferred Stock collectively, the “Purchasers” and each, a “Purchaser”), the Persons (as defined below) set forth on Exhibit B attached hereto (collectively, the
“Junior Holders” and each, a “Junior Holder”). 
 RECITALS 

WHEREAS, the Company and the holders of the outstanding shares of Series B Preferred Stock and the Junior Holders are parties to that
certain Investor Rights Agreement, entered into as of September 30, 2005, as amended (the “Existing Agreement”); 
 WHEREAS, pursuant to that certain Series C Preferred Stock Purchase Agreement, dated as of the date hereof (as amended from time to time, the “Purchase Agreement”), by and among
the Company and certain of the Purchasers, the Company has agreed to sell and issue shares of Series C Preferred Stock to such Purchasers; 
 WHEREAS, on September 14, 2006, the Company issued in favor of certain of its stockholders Warrants to Purchase Capital Stock of the Company which, as amended and restated on the date hereof (the
“Warrants”), are exercisable for the purchase of shares of the Series C-1 Preferred Stock; and 

WHEREAS, it is a condition to the obligations of the parties to the Purchase Agreement that this Agreement amend, restate and supersede
the Existing Agreement and be executed by the Company, the Purchasers and the Junior Holders. 
 NOW, THEREFORE, in
consideration of the mutual promises and covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as
follows: 
 1. Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings:

 “Affiliate” means, as applied to the Company or any other specified Person, any Person directly or indirectly
controlling, controlled by or under direct or indirect common control with the Company (or other specified Person) and shall also include, in the case of a specified Person who is an individual, any Family Member of such Person. 

  
 1 

 “Board” means the Company’s Board of Directors. 

“Certificate of Incorporation” means the Company’s Third Amended and Restated Certificate of Incorporation, as amended from
time to time in accordance with the terms thereof. 
 “Common Stock” means the Company’s Common Stock, $.001 par
value per share. 
 “Company Stock” means all shares of Common Stock, Series A Preferred Stock, Series B
Preferred Stock, Series C Preferred Stock and Series C-1 Preferred Stock and all other shares of the Company’s capital stock, including all classes of common, preferred, voting and nonvoting capital stock, now owned or hereafter acquired by any
Junior Holder or Purchaser. 
 “Convertible Securities” means securities or obligations that are exercisable for,
convertible into or exchangeable for shares of Company Stock, including shares of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock, options, warrants or other rights to subscribe for or
purchase Company Stock or obligations that are, directly or indirectly, exercisable for, convertible into or exchangeable for Company Stock. 

“Family Member” means, with respect to any individual, such individual’s parents, spouse, and descendants (whether natural
or adopted) and any trust or other vehicle formed solely for the benefit of, and controlled by, such individual and/or any one or more of them. 

“Fully-Diluted Basis” means, at the relevant time of determination, the number of shares of Common Stock assuming the conversion
or exchange of all outstanding convertible or exchangeable securities (including the conversion of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series C-1 Preferred Stock into Common Stock) and the exercise of
all then outstanding warrants, options or other rights to subscribe for or purchase any shares of Common Stock. 
 “Majority Electing
Purchasers” means, at any time, those Electing Purchasers (as defined in Section 2.3 hereof) holding at least sixty percent (60%) of the shares of Common Stock issued or issuable upon conversion of the Series C
Preferred Stock then held by all Electing Purchasers assuming the conversion of the Series C Preferred Stock held by such Electing Purchasers. 

“Majority Purchasers” means, at any time, those Purchasers holding at least sixty percent (60%) of the shares of Common
Stock issued or issuable upon conversion of the Series C Preferred Stock assuming the conversion of the Series C Preferred Stock held by such Purchasers. 
 “Offered Securities” means (a) any Common Stock, Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock or other Company
Stock or Convertible Securities, (b) any equity or debt security or stock option convertible into, or exercisable or exchangeable for, with or without consideration, any of the securities described in clause (a) above (including any option
to purchase or warrant exercisable for the purchase of such security), (c) any security carrying a right to subscribe to or purchase any security of the Company entitling the holder thereof to participate in dividend distributions or in the
distribution of assets upon the liquidation, dissolution or winding up of the Company, (d) any phantom stock or stock appreciation right and (e) any right to acquire the securities described in

  
 2 

 
clauses (a) through (d) hereof, provided, however, that “Offered Securities” does not include (i) shares of Common Stock issued pursuant to (1) the exercise of the
stock options granted pursuant to the Company’s 2004 Stock Option Plan, as amended from time to time, exercisable for up to eighteen percent (18%) of the Common Stock (calculated on a Fully-Diluted Basis) as of the completion of the sale
of Series C Preferred Stock, plus options to purchase up to 115,429 shares of Common Stock granted prior to October 1, 2005 (collectively, with the Corporation’s 2004 Stock Option Plan, the “Plan”), or
(2) stock options issued or granted after the date hereof pursuant to the Plan, to the extent that any stock options or restricted stock awards previously granted pursuant to the foregoing clause (1) are canceled or expire unexercised or
are repurchased at cost upon termination of employment or the applicable consulting arrangement with the Company; provided, that in each of the foregoing cases, such issuances and grants are approved by the Board, including a majority of the
directors appointed pursuant to Section 4.1(b)(i) below (ii) shares of Common Stock issued in a bona fide, firmly underwritten public offering registered under the Securities Act, pursuant to a registration statement on Form S-1;
(iii) shares of Common Stock issued upon exercise or conversion of the Series A Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock, the Series C-1 Preferred Stock, or any option, warrant or other convertible security
outstanding, and as in effect, on the date hereof; (iv) shares of Series C Preferred Stock issued under the Purchase Agreement and the shares of Common Stock issuable upon conversion of such shares, and shares of Series C-1 Preferred Stock
issuable upon exercise of the Warrants and shares of Common Stock issuable upon conversion of such shares; (v) shares of Series C Preferred Stock (or shares of Common Stock issued upon exercise or conversion of the such Series C Preferred
Stock) issuable in accordance with the warrant to be issued to Kevin Rakin pursuant to the Employment Agreement by and between the Company and Kevin Rakin; (vi) up to 174,214 shares of Common Stock or Series C-1 Preferred Stock (and shares of
Common Stock issued in the event of any conversion of such Series C-1 Preferred Stock) to third parties as compensation for services in connection with the completion of the initial sale of the Series C Preferred Stock and (vii) shares of
Common Stock (or options and warrants exercisable therefor), not issued for equity financing purposes, to strategic partners or other third parties in connection with commercial credit arrangements, equipment leases or debt financings, strategic
partnerships, licensing arrangements or other similar transactions, the terms of which are approved by the Board, including a majority of the directors appointed pursuant to Section 4.1(b)(i) below then serving. 

“Person” means natural persons, corporations, limited partnerships, general partnerships, limited liability
companies, joint stock companies, joint ventures, associations, companies, trusts, banks, trust companies, land trusts, business trusts or other organizations, whether or not legal entities, and governments and agencies and political subdivisions
thereof. 
 “QIPO” means a firmly underwritten public offering of the Company’s Common Stock registered
under the Securities Act with gross proceeds to the Company of not less than $20,000,000, at a price per share not less than $10.8486 (as adjusted for stock splits, dividends, recapitalizations and the like effected with respect to Common Stock
after the date hereof) and after giving effect to which the Company’s Common Stock is listed on a U.S. national securities exchange. 

  
 3 

 “Sale Transaction” shall have the meaning ascribed to such term in the Certificate
of Incorporation. 
 “Securities Act” means the Securities Act of 1933, as amended. 

“Series A Preferred Stock” means the Company’s Series A Preferred Stock, $.001 par value per share. 

“75% Purchasers” means, at any time, those Purchasers holding at least seventy-five percent (75%) of the shares of Common
Stock issued or issuable upon conversion of the Series C Preferred Stock assuming the conversion of the Series C Preferred Stock held by such Purchasers. 
 2. Preemptive Rights. 
 2.1 Offered Securities. Each
(a) Purchaser that is an “accredited investor” within the meaning of Regulation D as promulgated under the Securities Act, (b) ABH Investors Limited Liability Company so long as it holds at least fifty percent (50%) of the
shares of Series A Preferred Stock held by it on the date hereof (as adjusted for stock splits, dividends, recapitalizations and the like effected with respect to the Series A Preferred Stock after the date hereof) and as long as it is an
“accredited investor” within the meaning of Regulation D as promulgated under the Securities Act, and (c) Kevin Rakin, as long as he is an “accredited investor” within the meaning of Regulation D as promulgated under the
Securities Act (each, a “Qualified Purchaser”) shall have the right to purchase up to its pro rata share (as set forth in Section 2.2) of all Offered Securities (together with a right of over-subscription as set
forth in Section 2.4) that the Company may, from time to time, propose to sell or issue after the date of this Agreement. The Company shall issue Offered Securities only in accordance with the provisions of this Section 2.

 2.2 Qualified Purchasers’ Pro Rata Share. Each Qualified Purchaser’s pro rata share is equal to the ratio of
(a) the number of shares of Common Stock owned by such Qualified Purchaser immediately prior to the issuance of the Offered Securities (calculated on a Fully-Diluted Basis) to (b) the total number of shares of Common Stock owned by all
Qualified Purchasers immediately prior to the issuance of the Offered Securities (calculated on a Fully-Diluted Basis). 
 2.3
Exercise of Rights. If the Company proposes to issue any Offered Securities, it shall first give each Purchaser written notice of its intention, describing the Offered Securities, the price, the terms and the conditions upon which the Company
proposes to issue the same and, if applicable, the identity of the Persons to which the Offered Securities are intended to be offered (the “Notice”). Each Qualified Purchaser shall have ten (10) business days from the
delivery of the Notice to decide whether to purchase any portion of the Offered Securities, up to its pro rata share of the Offered Securities for the price specified in the Notice by giving written notice to the Company and stating therein the
quantity of Offered Securities, if any, that it elects to purchase (the “Election Notice”). If the consideration to be paid by others for the Offered Securities is not cash, the fair market value of the consideration shall be
determined in good faith by the Board and a reasonably detailed explanation of the Board’s determination of such value 

  
 4 

 
shall be included in the Notice. All Qualified Purchasers electing to participate in the offering of such Offered Securities (the “Electing Purchasers”) shall pay the cash
equivalent thereof as so determined; provided, however, that, in the event that the Majority Electing Purchasers disagree with the Board’s determination of the fair market value of such consideration, the Majority Electing Purchasers shall give
the Board written notice of such disagreement simultaneously with the delivery of the Election Notice (the “Valuation Dispute Notice”). The Board and the Majority Electing Purchasers shall negotiate in good faith to resolve
such disagreement and failing a resolution of such disagreement within ten (10) days after receipt of the Valuation Dispute Notice, the Board and the Majority Electing Purchasers shall mutually agree upon and select an independent nationally
recognized investment bank, accounting firm or other financial institution to determine such fair market value (the “Independent Evaluator”) not later than fifteen (15) days following the conclusion of such previous ten
(10) business day period. In the event that the Board and the Majority Electing Purchasers fail to mutually agree on an Independent Evaluator within such period, the Board and the Majority Electing Purchasers shall each select an Independent
Evaluator and the two (2) Independent Evaluators shall mutually agree upon and designate within ten (10) days following the designation of the two (2) Independent Evaluators as provided above a final Independent Evaluator who shall
determine such fair market value. In the event that either the Board or the Majority Electing Purchasers fail to so select an Independent Evaluator within such period, the Independent Evaluator so selected by the other shall be deemed to be the
final Independent Evaluator for purposes of this Section 2.3. The final Independent Evaluator’s determination of the fair market value of the securities shall be set forth in a written detailed report mutually addressed to the
Company and the Electing Purchasers and such determination shall be final, conclusive and binding upon the Company and the Electing Purchasers. All costs related to the appointment of and valuation by the Independent Evaluators shall be borne by the
Company. 
 2.4 Allocation of Undersubscriptions. If less than all of the Qualified Purchasers elect to purchase
their full pro rata share of the Offered Securities, then the Company shall promptly notify in writing the Electing Purchasers and shall offer such Electing Purchasers the right to acquire the remaining Offered Securities (the
“Unsubscribed Securities”). Each of the Electing Purchasers shall have five (5) business days (the “Oversubscription Election Period”) after receipt of such notice to
notify the Company of its election to purchase all or a portion of the Unsubscribed Securities (each such Electing Purchaser, an “Oversubscribing Purchaser”). If, as a result thereof, the Oversubscribing
Purchasers’ oversubscription exceeds the total number of Unsubscribed Securities available to be purchased, the Unsubscribed Securities shall be allocated among the Oversubscribing Purchasers on a pro rata basis in accordance with their
relative holdings of Series C Preferred Stock, Series C-1 Preferred Stock, Series B Preferred Stock and Series A Preferred Stock (determined on an as-converted basis), or as they otherwise agree among themselves. 

2.5 Third Party Sales of Offered Securities. If, following the Company’s compliance with this Section 2, the
Electing Purchasers fail to exercise in full their collective rights of first refusal with respect to the Offered Securities, the Company shall have sixty (60) days after the expiration of the Oversubscription Election Period to sell the
Offered Securities that the Electing Purchasers did not purchase at a price and upon terms and conditions no more favorable to the purchasers thereof than specified in the Notice. If the Company has not sold such Offered Securities within such sixty
(60)-day period, the Company shall not thereafter issue or sell any 

  
 5 

 
Offered Securities without first offering such Offered Securities to the Purchasers in the manner provided in this Section 2. 

2.6 Waiver. Any and all rights arising under this Section 2 with respect to the issuance of any Offered
Securities to any Person may be waived, either prospectively or retrospectively, by the Majority Purchasers and any such waiver shall be effective as to all Purchasers with such rights under this Section 2. 

3. Right to Force Sale. 

3.1 Right to Force Sale. In the event that the holders of at least sixty percent (60%) of the shares of Common Stock issuable
upon the conversion of the Series C Preferred Stock then outstanding (the “Approving Holders”) elect, by written notice to the Board, the Purchasers and the Junior Holders, to initiate and consummate a Sale Transaction (an
“Approved Sale”), all Purchasers and all Junior Holders shall vote in favor of, consent to and raise no objections against the Approved Sale, and, if requested by the Approving Holders, such Purchasers and Junior Holders
shall agree to sell all of their Company Stock and Convertible Securities on the terms and conditions approved by the Approving Holders. The Purchasers and Junior Holders shall take all actions that are reasonably requested by the Approving Holders
in connection with the consummation of the Approved Sale, including, without limitation, attendance at stockholders’ meetings in person or by proxy for the purposes of obtaining a quorum and the execution of written consents in lieu of
meetings, execution of such agreements and instruments such that any proposal or resolution reasonably requested by the Approving Holders in connection therewith shall be implemented by the Company and if the Company’s stockholders are entitled
to vote on any such matter, all of the voting Company Stock and Convertible Securities over which such Junior Holder and/or Purchaser has voting control shall be voted in favor of the proposal or resolution in connection with such transaction,
together with such other actions as are reasonably requested by the Approving Holders to effect the allocation and distribution of the aggregate consideration received upon the consummation of the Approved Sale in accordance with the terms of the
Certificate of Incorporation. Notwithstanding any other provision set forth in this Section 3.1, in connection with the Approved Sale, no Purchaser or Junior Holder shall be obligated, or liable to any Person, for an amount in excess of
the net amount that such Purchaser or Junior Holder actually receives in connection with such Approved Sale. 
 3.2
Obligations in Connection with Stock Sale. Within ten (10) days following the affirmative vote or written consent of the Approving Holders in favor of an Approved Sale under Section 3.1 in the form of a stock sale (the
“Tender Period”), each Purchaser and Junior Holder will tender all certificates representing his, her or its shares of Company Stock with the Secretary of the Company (the “Secretary”). The Secretary
shall hold such certificates in trust pending the consummation of the Approved Sale and, upon the Company’s receipt of the cash purchase price or other consideration given by an acquiror in such Approved Sale (the “Purchase
Consideration”), the Company shall deliver to each Purchaser and Junior Holder the portion of such Purchase Consideration payable to such Purchaser or Junior Holder in respect of his or its shares of Company Stock in accordance with the
terms of the Certificate of Incorporation. In the event that any Purchaser or Junior Holder does not comply with the requirements of this Section 3.2 and/or fails to tender his or its stock certificate(s) with the Secretary within the
Tender 

  
 6 

 
Period: (a) any Purchase Consideration received by the Company in respect of shares of Company Stock held by such non-tendering Purchaser or Junior Holder (a “Non-Tendering
Purchaser”) shall be held by the Company in trust for the benefit of such Non-Tendering Purchaser; (b) any non-tendered stock certificate(s) held by such Non-Tendering Purchaser shall, automatically and without further action, be
deemed to be “tendered” and all shares of Company Stock represented by such non-tendered stock certificate(s) shall be deemed transferred to the acquiror upon the consummation of the Approved Sale; and (c) the Company shall issue in
the name of each Non-Tendering Purchaser, in lieu of any non-tendered stock certificate(s) held by such Non-Tendering Purchaser, a phantom stock certificate (the “Phantom Certificate”), which evidences only a Non-Tendering
Purchaser’s right to receive from the Company his, her or its portion of the Purchase Consideration upon the consummation of an Approved Sale. Promptly following the Tender Period, the Company shall deliver all Phantom Certificates to the
Secretary and the Secretary shall hold the Phantom Certificate issued to each Non-Tendering Purchaser in trust until such time as such Non-Tendering Purchaser delivers all of his or its non-tendered stock certificates to the Secretary in exchange
for his or its Phantom Certificate. Upon the consummation of an Approved Sale, each holder of a Phantom Certificate shall be entitled to receive from the Company that portion of Purchase Consideration specified in the Phantom Certificate.

 3.3 Waiver of Appraisal Rights; Further Actions. Each Junior Holder and Purchaser agrees to waive any and all
dissenters and appraisal rights they may have under applicable law in connection with an Approved Sale, and to take any and all further actions reasonably requested by the Approving Holders or otherwise required to effectuate the Approved Sale.

 3.4 Subject to Certificate of Incorporation. Nothing contained herein shall eliminate or otherwise modify any consent
and approval requirements under the Certificate of Incorporation with respect to an Approved Sale. 
 3.5 Waiver of
Rights. The exercise or non-exercise by the Approving Holders of their rights pursuant to this Section 3 with respect to a proposed Sale Transaction shall be without prejudice to such Approving Holders’ rights under this
Section 3 with respect to any subsequent Sale Transaction. 
 3.6 Irrevocable Proxy. SOLELY IN CONNECTION
WITH THE EFFECTUATION OF THE TRANSACTIONS CONTEMPLATED BY THIS SECTION 3, EACH JUNIOR HOLDER AND PURCHASER HEREBY EXPRESSLY AND IRREVOCABLY APPOINTS THE COMPANY’S CHIEF EXECUTIVE OFFICER AS SUCH JUNIOR HOLDER’S AND PURCHASER’S
PROXY AND ATTORNEY-IN-FACT TO VOTE SUCH JUNIOR HOLDER’S AND PURCHASER’S COMMON STOCK, PREFERRED STOCK AND OTHER SECURITIES OF THE COMPANY WITH VOTING OR APPROVAL RIGHTS AND TAKE ANY AND ALL SUCH OTHER ACTION WITH RESPECT TO SUCH COMMON
STOCK AND PREFERRED STOCK AND ALL OTHER SECURITIES OF THE COMPANY AS THE APPROVING HOLDERS MAY DIRECT, BUT SOLELY IN CONNECTION WITH A TRANSACTION EFFECTED IN ACCORDANCE WITH SECTION 3 ABOVE. THIS PROXY IS COUPLED WITH AN INTEREST AND IS
VALID FOR A PERIOD OF TEN (10) YEARS FROM THE DATE OF THIS AGREEMENT. 

  
 7 

 3.7 Legend. All certificates representing shares of Company Stock and Convertible
Securities owned or hereafter acquired by the Junior Holders and Purchasers or any transferee of the Junior Holders or Purchasers bound by this Agreement shall have affixed thereto a legend substantially in the following form: 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN OBLIGATIONS, RESTRICTIONS, PROXIES AND VOTING AGREEMENTS AS
SET FORTH IN A CERTAIN AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT, AS AMENDED FROM TIME TO TIME, BY AND AMONG THE STOCKHOLDER, THE COMPANY AND CERTAIN OTHER STOCKHOLDERS, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY”

 4. Voting Rights. 
 4.1 Election of Directors. The Junior Holders and the Purchasers agree to vote all voting Company Stock and Convertible Securities over which such Person has voting control, whether now owned or
acquired hereafter and shall take all other necessary or desirable actions within his or its control and the Company shall take all necessary or desirable actions within its control (including, without limitation, calling special Board and
stockholder meetings), so as to cause: 
 (a) The authorized number of directors on the Board to be established at seven
(7) members; 
 (b) The following individuals to be elected to the Board at each meeting to elect, and pursuant to each
consent executed for the purpose of electing, the members of the Board: 
 (i) four (4) individuals designated by holders
of a majority of the voting power of all of the Series C Preferred Stock, voting together as a single class; provided, that (A) one (1) such director shall be designated by Safeguard Delaware, Inc. (“Safeguard”),
which director shall initially be Gary Kurtzman; (B) one (1) such director shall be designated by Canaan VII L.P. (“Canaan”), which position shall initially be left vacant; (C) one (1) such director shall
be designated by Channel Medical Partners, L.P. (“Channel”), which director shall initially be Carol Winslow; and (D) one (1) such director shall be an individual who is not an employee or other Affiliate of either
the Company or Safeguard who is designated by Safeguard, which position shall initially be left vacant; 
 (ii) two
(2) individuals designated by the holders of a majority of the voting power of all of the Series B Preferred Stock, voting together as a single class; provided, that (A) one (1) such director shall be designated by Canaan, which
director shall initially be Stephen M. Bloch; and (B) one (1) such director shall be designated by Wheatley New York Partners, LP (“Wheatley”), who shall initially be David Dantzker; and 

(iii) one (1) individual who is the person then serving as the Chief Executive Officer of the Company, and who shall initially be
Kevin Rakin. 

  
 8 

 (c) In the event of any vacancy on the Board, to fill such vacancy with a representative
designated in the same manner as the person who held the directorship so vacated as set forth above. 
 If (i) Safeguard
requests that either director designated by Safeguard be removed (with or without cause) by written notice to the Company, the Purchasers and the Junior Holders, (ii) Canaan requests that either director designated by Canaan be removed (with or
without cause) by written notice to the Company, the Purchasers and the Junior Holders, (iii) Channel requests that the director designated by Channel be removed (with or without cause) by joint written notice to the Company, the Purchasers and
the Junior Holders, or (iv) Wheatley requests that the director designated by Wheatley be removed (with or without cause) by written notice to the Company, the Purchasers and the Junior Holders, then, in each such case, such director shall be
removed and each Purchaser and Junior Holder hereby agrees to vote all shares of Common Stock, Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock Series C-1 Preferred Stock and any other voting securities of the Company
over which such Purchaser or Junior Holder has voting control to effect such removal or to consent in writing to effect such removal upon such request. Each person who is or becomes a member of the Board because he or she is serving as the Chief
Executive Officer of the Company shall serve as a director only for as long as such person remains the Chief Executive Officer of the Company and shall only be replaced by any new or interim Chief Executive Officer of the Company. 

4.2 Subsidiary Boards and Committees. Any committee established by the Board shall consist of no more than three members, one
(1) of whom shall be the director designated by Safeguard, one (1) of whom shall be the director designated by Canaan and one (1) of whom shall be appointed by the Board. All actions of each committee of the Board shall require the
affirmative vote of a majority of the members of such committee. The composition of the board of directors of each subsidiary of the Company and of each committee thereof shall, where the appropriate persons are willing to serve, be consistent with
the composition of the Board and each corresponding committee thereof; provided that no member of the Board shall be required to serve as a director or committee member of any such subsidiary. 

4.3 Board Observation Rights. The holders of at least a majority of the voting power of the then outstanding shares of Series A
Preferred Stock have a right to appoint (and replace) one (1) individual, and Safeguard shall have a right to appoint (and replace) one (1) individual, and Red Abbey Venture Partners (QP), LP shall have a right to appoint (and replace) one
(1) individual (all such individuals, the “Observers”) to attend, at their own cost and expense, any meeting of the Board as long as the applicable Observer has executed a confidentiality agreement satisfactory to the
Company, except that any Observer may be excluded from any presentation or discussion of any topic that would present an actual or apparent conflict of interest between the Company and such Observer or any affiliate of such Observer or any
presentation or discussion involving material matters which, if provided to or attended by such Observer would, in the reasonable opinion of counsel to the Company, jeopardize the attorney client privilege that would otherwise be afforded to such
presentation or discussion. The Observers shall not have the right to vote on any matter presented to the Board. Subject to the restrictions set forth in this Section 4.3, the Company shall give the Observers notice of each meeting
thereof at the same time and in the same manner as the members of the Board receive notice of such meetings, and the Company shall permit the Observers to attend as an observer at all meetings thereof and shall

  
 9 

 
provide the Observers with all materials provided by the Company to the Board in connection with such meetings, subject to the confidentiality obligation above and the right of the Company to
withhold such information to the extent that providing such information would present an actual or apparent conflict of interest between the Company and such Observer or any affiliate of such Observer or to the extent that such information involves
material matters which, if provided to such Observer would, in the reasonable opinion of counsel to the Company, jeopardize the attorney client privilege that would otherwise be afforded to such information. 

4.4 Meetings. The Company shall use commercially reasonable efforts to cause the Board to meet at least once each fiscal quarter
of the Company. 
 5. Information Rights and Other Covenants. 
 5.1 Inspection. The Company shall permit each Purchaser, or any authorized representative of a Purchaser, to visit and inspect the properties of the Company and its subsidiaries, including its
corporate and financial records, and to discuss its business and finances with officers of the Company and its subsidiaries, during normal business hours following reasonable notice, as often as may be reasonably requested. 

5.2 Directors’ Expenses. The Company shall reimburse the directors on the Board for all reasonable out-of-pocket expenses
incurred by them in connection with attendance at all meetings of the Board (including any meetings of committees of the Board) and the board of directors of each of the Company’s subsidiaries (including any meetings of committees thereof).

 5.3 Financial Statements and Other Information. The Company and its subsidiaries shall maintain true books and records
of account in which full and correct entries shall be made of all its business transactions pursuant to a system of accounting established and administered in accordance with United States generally accepted accounting principles consistently
applied, and shall set aside on its books all such proper accruals and reserves as shall be required under generally accepted accounting principles consistently applied. 
 (a) The Company shall deliver to each Purchaser as long as such Purchaser holds at least fifty percent (50%) of the shares of Series B Preferred Stock and/or Series C Preferred Stock held by such
Purchaser on the date hereof (as adjusted for stock splits, dividends, recapitalizations and the like effected with respect to the Series B Preferred Stock after the date hereof) and to ABH Investors Limited Liability Company as long as it holds at
least fifty percent (50%) of the shares of Series A Preferred Stock held by it on the date hereof (as adjusted for stock splits, dividends, recapitalizations and the like effected with respect to the Series A Preferred Stock after the date
hereof): 
 (i) within twenty (20) days following the end of each month, unaudited Financial Statements (as defined below)
for such month and for the current fiscal year to date, including a budget variance analysis with respect to such month; 

(ii) within thirty (30) days following the end of each fiscal quarter, unaudited Financial Statements for such quarter and for the
current fiscal year to date; 

  
 10 

 (iii) within one-hundred and twenty (120) days following the end of each fiscal year,
audited financial statements for such fiscal year; and 
 (iv) at least thirty (30) days prior to the beginning of each
fiscal year, an annual operating plan and budget for the Company and its subsidiaries (the “Annual Budget”), prepared on a monthly basis for the ensuing fiscal year, and on a basis consistent with prior periods (including,
among other items, appropriate reserves, accruals and provisions for income taxes) and representing the best estimate of the Company based upon available information. The Annual Budget must be approved by the Board with the consent of the Majority
Purchasers, no later than ten (10) days prior to the beginning of the following fiscal year. Such Annual Budget shall include underlying assumptions and a brief qualitative description of the Company’s operating plan by the Chief Executive
Officer or Chief Financial Officer in support of the Annual Budget. The Company shall also furnish to each Purchaser, within a reasonable time of its preparation, material amendments to the Annual Budget, if any, which material amendments must be
approved by the Board with the consent of the Majority Purchasers. 
 (b) The Company’s “Financial
Statements” shall include a balance sheet, statement of earnings, stockholders’ equity and cash flows for the Company and its subsidiaries for the applicable periods, setting forth in each case in comparative form the figures from
the previous period with variances delineated, prepared in accordance with generally accepted accounting principles consistently applied, all certified by the Company’s Chief Executive Officer or Chief Financial Officer to (i) have been
prepared in accordance with United States generally accepted accounting principles consistently applied, with the exception that unaudited financial statements need not have notes attached and are subject to year-end audit adjustments and
(ii) present fairly in all material respects the consolidated financial position of the Company as of the dates specified and the results of their respective operations and changes in financial position with respect to the periods specified
(subject in the case of interim financial statements only to normal year-end audit adjustments described in reasonable detail). The “MD&A” section of the Financial Statements shall include a budget variance analysis and
management’s discussion and analysis of the Financial Statements related thereto. With respect to the audited Financial Statements referenced in Section 5.3(a)(iii) above, each of the Financial Statements delivered in accordance
with such section shall be certified without qualification by an accounting firm acceptable to the Majority Purchasers auditing the same to have been prepared in accordance with generally accepted accounting principles consistently applied. The
Company shall also deliver to each Purchaser simultaneously with the delivery of such annual Financial Statements a copy of the so called “management letter” issued by the auditors in connection with such annual financial statements.

 (c) If the Company fails to provide the reports or Financial Statements required by this Section 5.3, the
Majority Purchasers may give the Company written notice requesting immediate delivery of such reports. If the Company fails to deliver such reports within ten (10) business days of the receipt of such notice, then the Majority Purchasers shall
have the right and authority, at the Company’s sole expense, to request an audit by a single accounting firm of its or their choice, such that the reports or financial statements are produced to its or their sole satisfaction. 

  
 11 

 (d) The Company shall provide to such Purchaser: 

(i) Within ten (10) days after filing, copies of all material documents filed by the Company with the Securities and Exchange
Commission, 
 (ii) within ten (10) days after filing, all pleadings of any material lawsuits filed by or against the
Company or its subsidiaries, and 
 (iii) within ten (10) days after receipt, copies of any notices regarding any material
defaults under any agreement or contract to which the Company or any of its subsidiaries is a party or is bound. 
 5.4
Liability Insurance; Directors’ and Officers’ Liability Insurance. Each of the Company and its subsidiaries shall obtain, or be an insured party pursuant and beneficiary pursuant to, a general liability insurance policy (including
federal flood insurance if the Company’s or any of the Company’s subsidiaries’ business is located in a designated Federal Flood Area), a product liability insurance policy and a directors’ and officers’ liability insurance
policy, in each such case on terms and conditions that are reasonably acceptable to the Board, including a majority of the directors appointed pursuant to Section 4.1(b)(i) hereof then serving. The Company (and its subsidiaries, to the
extent that such subsidiaries obtain such policies) shall maintain such policies in full force and effect at all times. 
 5.5
Stock Vesting; Stock Restriction Agreements. 
 (a) Unless otherwise approved by the Board, including all of the
directors appointed pursuant to Section 4.1(b)(i) hereof then serving: 
 (i) all stock options and other stock
equivalents issued after the date of this Agreement to employees, directors, consultants and other service providers shall be subject to vesting on terms no less favorable to the Company than as follows: (a) twenty-five percent (25%) of
such stock shall vest at the end of the first year following the earlier of the date of issuance or such person’s services commencement date with the Company, and (b) seventy-five percent (75%) of such stock shall vest in equal
monthly installments over the subsequent three (3)-year period; 
 (ii) with respect to any shares of restricted stock
purchased by any employee, director, consultant or service provider, the Company’s repurchase option shall provide that upon such person’s termination of employment or service with the Company, with or without cause, the Company or its
assignee (to the extent permissible under applicable securities laws and other laws) shall have the option to purchase at original cost any unvested shares of stock held by such person; and 

(iii) all stock options and other stock equivalents issued after the date of this Agreement to employees, directors, consultants and
other service providers shall not be subject to any acceleration of vesting upon a Sale Transaction. 

  
 12 

 (b) The Company shall enter into a stock option agreement, in form and substance
satisfactory to the Board with the consent of the Majority Purchasers, with each employee, director, consultant and service provider who is issued any Company stock options. 
 (c) The Company shall not grant or sell any stock option or other stock equivalent to any employee, director, consultant or other service provider or amend the terms relating thereto without the prior
consent of the Board. 
 5.6 Reservation of Common Stock. The Company shall at all times reserve and keep available,
solely for issuance and delivery upon the conversion of the Series C Preferred Stock, the Series C-1 Preferred Stock and the Series B Preferred Stock, all Common Stock issuable from time to time upon such conversion. 

5.7 Proprietary Rights Agreement. The Company and each of its subsidiaries shall require all employees, officers and consultants
to execute and deliver a Non-Disclosure and Invention Assignment Agreement in the form attached to the Purchase Agreement. 

5.8 Directors’ Liability and Indemnification. The Company’s and each of its subsidiaries’ certificate of
incorporation, bylaws and other organizational documents shall provide (a) for elimination of the liability of directors to the maximum extent permitted by law and (b) for indemnification of directors for acts on behalf of the Company and
its subsidiaries to the maximum extent permitted by law. 
 5.9 Qualified Small Business Stock. The Company will not take
any action that would cause the Series C Preferred Stock, the Series C-1 Preferred Stock or the Series B Preferred Stock to not qualify as “Qualified Small Business Stock” under Section 1202 of the Internal Revenue Code of 1986, as
amended. The Company will use reasonable efforts to comply with the reporting and record keeping requirements of Section 1202 of the Internal Revenue Code of 1986, as amended, any regulations promulgated thereunder and any similar state laws
and regulations and agrees not to repurchase any stock of the Company if such repurchase would cause such shares not to so qualify as “Qualified Small Business Stock.” 

5.10 Intellectual Property. The Company will, and will cause each of its subsidiaries to, possess and maintain all Intellectual
Property (as such term is defined in the Purchase Agreement) necessary to the conduct of their respective businesses and own all right, title and interest in and to, or have a valid license for, all Intellectual Property used by the Company or such
subsidiary in the conduct of its business. The Company will not take any action, or fail to take any action, and will prevent each of its subsidiaries from taking any action or failing to take any action, that would result in the invalidity, abuse,
misuse or unenforceability of such Intellectual Property or that would infringe upon any rights of any other Person. 
 5.11
Board of Director Approval. The Company shall not, and shall not permit any subsidiary to, without the approval of a majority of the Board, including a majority of the directors designated pursuant to Section 4.1(b) hereof then
serving: (a) except with respect to regularly scheduled payments under the Venture Loan and Security Agreement, dated as of December 21, 2006, by and between the Company and Horizon Technology Funding Company LLC, as in effect on the date
hereof, incur indebtedness, or repay or satisfy outstanding 

  
 13 

 
indebtedness, in excess of $200,000, (b) make any loan or advance to an employee, except in the ordinary course of business as part of travel advances or similar expense advances,
(c) guarantee any indebtedness or obligation of any other party, except in the ordinary course of business, (d) own any stock or other securities of any subsidiary company or other corporation, partnership or entity unless it is
wholly-owned by the Company, (e) make any material change in the nature of its business as presently conducted or presently contemplated to be conducted, (f) approve or pay any (i) discretionary or performance bonus or award to any
employee, consultant or advisor of the Company or any subsidiary thereof or (ii) severance or other similar payment upon termination of any relationship with the Company to any employee, consultant or advisor of the Company or any subsidiary
thereof, (g) hire any employee or officer above the Vice President level or with annual salary in excess of $200,000, (h) lease or purchase real estate property, (i) approve any stock option or incentive stock grant or purchase,
(j) lease or purchase any real property or (k) enter into any obligation or commitment in excess of $200,000, or make any single or series of related expenditures in excess of $200,000, except to the extent that such obligation, commitment
or expenditure is specifically provided for in the Annual Budget for the fiscal year in which such obligation, commitment or expenditure arises. 
 5.12 Subsidiaries. The Company will not, without the approval of a majority of the Board, including the affirmative vote or consent of a majority of the directors designated pursuant to
Section 4.1(b) hereof then serving: (a) organize or acquire any entity that is a subsidiary unless such subsidiary is wholly owned by the Company, (b) permit any subsidiary to consolidate or merge into or with any entity or
sell or transfer all or substantially all its assets, except that the Company may permit a subsidiary to consolidate or merge into or with or sell or transfer assets to any other subsidiary or (c) sell or otherwise transfer any shares of
capital stock of any subsidiary or other equity securities of any entity, except to the Company or another subsidiary, or permit any subsidiary to issue, sell or otherwise transfer any shares of its capital stock or the capital stock of any
subsidiary or other equity securities of any entity or to sell all or substantially all of such subsidiary’s assets, except to the Company or another subsidiary. 
 5.13 State of New York Presence. The Company shall maintain an office in the State of New York until such time as Wheatly shall no longer be a stockholder of the Company. 

5.14 Confidentiality. Each Purchaser and ABH Investors Limited Liability Company agrees that such Person will keep confidential
and will not disclose or divulge or use for any purpose, other than monitoring its investment in the Company, any confidential information obtained from the Company pursuant to the terms of this Agreement, unless such confidential information
(a) is known or becomes known to the public in general (other than as a result of a breach of this Section 5.14 by such Person); (b) is or has been independently developed or conceived by such Person without use of the
Company’s confidential information; or (c) is or has been made known or disclosed to such Person by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that any
such Person may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to
any prospective purchaser of any Company Stock from such Person, if such prospective purchaser is bound by the provisions of this Section 5.14; (iii) to any affiliate, partner, member, stockholder or wholly owned subsidiary of such
Person in the ordinary course of such Person’s business, provided that such third party is bound by a 

  
 14 

 
confidentiality obligation with respect to such confidential information of the Company, such Person informs such third party that such information is confidential and directs such third party to
maintain the confidentiality of such information to the same extent as set forth in this Section 5.14; or (iv) as may otherwise be required by any national securities exchange, law, regulation or judicial interpretation, provided
that, to the extent reasonably practicable based upon the circumstances, the Company have a reasonable opportunity to seek a protective order or other protection with respect to such confidential information. The Company acknowledges that certain of
the Purchasers (including, without limitation, each of the Majority Purchasers) are in the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises
that may have products or services that compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict any Purchaser from investing or participating in any particular enterprise, regardless
of whether such enterprise has products or services that compete with those of the Company. 
 5.15 Change of Business.
The Company may not, without the prior written approval of the 75% Purchasers, engage, or permit any subsidiary of the Company to engage, in any business other than the business in which the Company is engaged on the date hereof. 

6. Termination. The rights and obligations set forth in this Agreement, except for those set forth in Articles 1 and 7 and Section 5.14,
shall terminate upon the earlier of (a) the effective date of the registration statement pertaining to the QIPO and (b) a Sale Transaction, provided, however, such rights and obligations shall not terminate upon the closing of such Sale
Transaction if such Sale Transaction is a sale, conveyance, exclusive license or disposition of all or substantially all of the assets of the Company unless the Majority Purchasers otherwise agree in writing. 

7. General. 
 7.1
Severability. If any term of provision of this Agreement is determined to be illegal, unenforceable or invalid in whole or in part for any reason, such illegal, unenforceable or invalid provisions or party thereof shall be stricken from this
Agreement, and such provision shall not affect the legality, enforceability or validity of the remainder of this Agreement. If any provision or part thereof of this Agreement is stricken in accordance with the provisions of this
Section 7.1, then such stricken provision shall be replaced, to extent possible, with a legal, enforceable and valid provision that is as similar in tenor to the stricken provision as is legally possible. 

7.2 Specific Performance. In addition to any and all other remedies that may be available at law, in the event of any breach of
this Agreement, each Purchaser shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunctive or other equitable relief as may be granted by a court of competent jurisdiction. The
parties hereto agree and acknowledge that money damages would not be an adequate remedy for any breach of the provisions of this Agreement and that the Company or any Purchaser may in its sole discretion apply to any court of law or equity or
competent jurisdiction 

  
 15 

 
for specific performance and/or injunctive relief (without posting a bond or other security) in order to enforce or prevent any violation of the provisions of this Agreement. 

7.3 Remedies Cumulative. No remedy or election hereunder shall be deemed exclusive but shall, wherever possible, be cumulative
with all other remedies at law or in equity. 
 7.4 Jury Trial Waiver. To the fullest extent permitted by law, and as
separately bargained-for-consideration, each party hereby waives any right to trial by jury in any action, suit, proceeding or counterclaim of any kind arising out of or relating to this Agreement. 

7.5 Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Delaware, as applicable to contracts executed and delivered in Delaware between Delaware residents and that are to be performed wholly within Delaware, without regard to principles of conflicts of law except with respect to matters of law concerning
the internal corporate affairs of any corporation that is a party to or the subject of this Agreement, which matters shall be governed by the law of the jurisdiction under which such corporation derives its powers. 

7.6 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon
personal delivery to the party to be notified, (b) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (c) one (1) business day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at the address as set forth on the signature page hereof, to a Purchaser at such Purchaser’s
address set forth on Exhibit A attached hereto and to a Junior Holder at such Junior Holder’s address set forth on Exhibit B attached hereto or at such other address as the Company, a Purchaser or Junior Holder may
designate by ten (10) days advance written notice to the other parties hereto. 
 7.7 Transfer of Rights. The rights
of each Purchaser under this Agreement, including, but not limited to, the preemptive rights granted to the Purchasers under Section 2 hereof, may be transferred to a transferee or assignee of shares of the Series C Preferred Stock, the
Series C-1 Preferred Stock and the Series B Preferred Stock or any shares of Common Stock issued or issuable upon conversion of the Series C Preferred Stock, the Series C-1 Preferred Stock and the Series B Preferred Stock; provided that the
Purchaser shall, within ten (10) business days after such transfer, furnish to the Company written notice of the name and address of such transferee or assignee and the number of shares with respect to which such rights are being assigned. The
transferee or assignee of a Purchaser’s rights and obligations hereunder shall be deemed a “Purchaser” for purposes of this Agreement without any further action required to be taken by the Company or any other Person. In addition,
notwithstanding anything to the contrary contained in Section 7.8 below, the applicable Exhibits hereto shall automatically be amended to give effect to such transfer or assignment. 

7.8 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be
waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the Majority Purchasers; provided, however, that any amendment to or waiver of Section 4 that

  
 16 

 
would adversely affect the rights of Safeguard, Canaan or Wheatley under Section 4 shall require the prior written consent of Safeguard, Canaan or Wheatley, respectively, and,
provided further, that no amendment or waiver that adversely affects the rights or increases the obligations of any Purchaser shall be effective without the written consent of such Purchaser, unless such amendment or waiver adversely affects the
rights or increases the obligations of all Purchasers in a like manner. Any amendment or waiver effected in accordance with this Section 7.8 shall be binding upon the Company and each of the Purchasers and Junior Holders and their
respective successors and assigns. 
 7.9 No Waiver. No waiver of any provision or consent to any action shall constitute
a waiver of any other provision or consent to any other action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or commit a party to provide a waiver in the future except to the extent specifically set
forth in writing. 
 7.10 Entire Agreement; Amendment and Restatement of Existing Agreement. This Agreement and exhibits
referred to herein constitute the entire agreement among the parties and supersede all prior communications, representations, understandings and agreements of the parties with respect to the subject matter hereof. All exhibits hereto are hereby
incorporated herein by reference. Nothing in this Agreement, express or implied, is intended to confer upon any third party any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this
Agreement. Each of the Company and each Purchaser that is a party to the Existing Agreement hereby expressly consents and agrees to this amendment and restatement of the Existing Agreement. 

7.11 Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine,
feminine or neutral forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. 
 7.12
Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document. This Agreement may be
executed by facsimile signatures. 
 7.13 Section Headings. The section headings are for the convenience of the parties
and in no way alter, modify, amend, limit or restrict the contractual obligations of the parties. 
 7.14 Joinder. The
Company shall require any Person that acquires, at any time following the date of this Agreement, Company Stock or Convertible Securities representing any shares of Common Stock then outstanding (calculated on a Fully-Diluted Basis) to, upon and as
a condition to such acquisition, execute a joinder pursuant to which such Person agrees to become subject to the obligations and restrictions applicable to a Junior Holder pursuant to the terms of this Agreement, except to the extent that such
Person shall be deemed a Purchaser pursuant to Section 7.7 above. 
 7.15 General Interpretation. The terms
of this Agreement have been negotiated by the parties hereto and the language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent. This Agreement shall be construed

  
 17 

 
without regard to any presumption or rule requiring construction against the party causing such instrument or any portion thereof to be drafted, or in favor of the party receiving a particular
benefit under this Agreement. No rule of strict construction will be applied against any Person. 
 7.16 Aggregation of
Stock. For the purpose of determining the availability of any rights under this Agreement that may be based upon the number of shares of Company Stock held by a party hereto, all shares of Company Stock held by such Person together with all
shares of Company Stock held by such Person’s Affiliates shall be aggregated together in all such required calculations. 

7.17 Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the respective successors and permitted assigns of the parties. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by the Company. Any attempted assignment made in
contravention of this Agreement shall be null and void and of no force or effect. 
 7.18 Expenses. The Company shall
pay, and hold the Purchasers harmless against liability for the payment of the reasonable fees and expenses incurred with respect to the enforcement of the rights granted under, or any amendments or waivers to, this Agreement. 

7.19 Stockholder Distinction. Any party hereto who holds or hereafter holds more than one class or series of Company Stock shall,
for all purposes hereof, be bound by this Agreement as to all shares of Common Stock (other than shares of Common Stock issued upon conversion of the Series B Preferred Stock, Series C Preferred Stock or Series C-1 Preferred Stock) and Series A
Preferred Stock as a “Junior Holder” hereunder and, as to all shares of Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and/or shares of Common Stock issued upon conversion of the Series B Preferred Stock,
Series C Preferred Stock and/or Series C-1 Preferred Stock held by such holder, as a “Purchaser” hereunder. 

[Signatures on following pages] 

  
 18 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights
Agreement as of the date first above written. 
  

			
	COMPANY:
	
	ADVANCED BIOHEALING, INC.
		
	By:	 	 /s/ Kevin Rakin

		 	Name: Kevin Rakin
		 	Title: President and Chief Executive Officer

			
		
	Address:	 	10933 N. Torrey Pines Road
		 	Suite 200
		 	La Jolla, CA 92037
		 	Attention: Kevin Rakin
		 	Facsimile: 858-754-3805

  
 19 

 
			
	JUNIOR HOLDERS:
	
	ABH INVESTORS LIMITED LIABILITY COMPANY
		
	By:	 	 /s/ Robert Graifman

		 	Name: Robert Graifman
		 	Title:   Managing Member
	
	  

	DR. HOWARD GREEN
	
	  

	DR. WALID KURI-HARCUCH
	
	  

	MEYTHA MARSCH DE KURI
	
	  

	THOMAS V. HENNESSY
	
	 /s/ JD Bernardy

	JD BERNARDY
	
	 /s/ Edward R. Gates

	ED GATES, ESQ.
	
	  

	HENRY LEWIS
	
	 /s/ Donald R. Kiepert

	DONALD R. KIEPERT,JR.

  
 [Signature
page to Amended and Restated Investor Rights Agreement] 
 20 

 
			
	  

	PETER B. FINN
	
	  

	THOMAS KOTTLER
	
	 /s/ Federico Castro-Munozledo 22/02/2007

	DR. FEDERICO CASTRO-MUNOZLEDO
	
	 /s/ David Dove

	DR. DAVID DOVE
	
	 /s/ David Eisenbud

	DR. DAVID EISENBUD
	
	  

	SALAZAR OLIVO
	
	  

	PETER FITZGERALD, MD
	
	WALTER GREENBLATT ASSOCIATES, LLC
		
	By:	 	 /s/ Walter C. Greenblatt

		 	Name: Walter Greenbatt
		 	Title:   Managing Director
	
	OCEANA PARTNERS
		
	By:	 	 /s/ Courtlandt Miller

		 	Name: Courtlandt G. Miller
		 	Title:   Managing Director

  
 [Signature
page to Amended and Restated Investor Rights Agreement] 
 21 

 
					
	 	 	 /s/ Kevin Rakin

		 	KEVIN RAKIN
	
	 PURCHASERS:

		
		 	SAFEGUARD DELAWARE, INC.
			
		 	By:	 	 /s/ Steven Feder

		 		 	Name: Steven J. Feder
		 		 	Title:   Vice President
		
		 	CHANNEL MEDICAL PARTNERS, L.P.
			
		 	By:	 	 Channel Medical Management, LLC
     and its General Partner

			
		 	By:	 	 Channel Medical Advisors, Inc.
     its Manager

			
		 	By:	 	 /s/ Carol D. Winslow

		 		 	    Carol D. Winslow
		 		 	    Secretary
		
		 	RED ABBEY VENTURE PARTNERS (QP), LP
			
		 	By:	 	 Red Abbey Ventures Partners, LLC, its
 General Partner

			
		 	By:	 	 /s/ Matt Zuga

		 		 	    Matt Zuga
		 		 	    Managing Member
		
		 	RED ABBEY VENTURE PARTNERS, LP
			
		 	By:	 	Red Abbey Ventures Partners, LLC, its
		 		 	General Partner
			
		 	By:	 	 /s/ Matt Zuga

		 		 	    Matt Zuga
		 		 	    Managing Member

  
 [Signature
page to Amended and Restated Investor Rights Agreement] 
 22 

 
			
	RED ABBEY CEO’S FUND, LP
		
	By:	 	Red Abbey Ventures Partners, LLC, its
		 	General Partner
		
	By:	 	 /s/ Matt Zuga

		 	     Matt Zuga
		 	     Managing Member
	
	CANAAN VII L.P.
		
	By:	 	Canaan Partners VII, LLC
		
	By:	 	 /s/ illegible

		 	Name:
		 	Title: Manager
	
	HUTTON LIVING TRUST dated 12/10/96
		
	By:	 	 /s/ Wende Hutton

		 	Wende Hutton
		 	Trustee
	
	WHEATLEY NEW YORK PARTNERS, L.P.
		
	By:	 	Wheatley NY Partners, LLC, General Partner
		
	By:	 	 /s/ Barry Rubenstein

		 	Name: Barry Rubenstein
		 	Title:   CEO
	
	WHEATLEY PARTNERS III, L.P.
		
	By:	 	Wheatley Partners III, LLC, General Partner
		
	By:	 	 /s/ Barry Rubenstein

		 	Name: Barry Rubenstein
		 	Title:   CEO

  
 [Signature
page to Amended and Restated Investor Rights Agreement] 
 23 

 
			
	WHEATLEY ASSOCIATES III, L.P.
		
	By:	 	Wheatley Partners III, LLC, General Partner
		
	By:	 	 /s/ Barry Rubenstein

		 	Name: Barry Rubenstein
		 	Title: CEO
	
	WHEATLEY FOREIGN PARTNERS III, L.P.
		
	By:	 	Wheatley Partners III, LLC, General Partner
		
	By:	 	 /s/ Barry Rubenstein

		 	Name: Barry Rubenstein
		 	Title: CEO
	
	OLIVER D. CURME CHILDREN’S TRUST
		
	By:	 	  

		 	Name:
		 	Title:
	
	EDWARD R. GATES AND LIORA L. GATES
	
	 /s/ Edward R. Gates

	
	 /s/ Liora L. Gates

	
	WALTER GREENBLATT & ASSOCIATES, LLC
		
	By:	 	 /s/ Walter C. Greenblatt

		 	Name: Walter C. Greenblatt
		 	Title: Managing Director

  
 [Signature
page to Amended and Restated Investor Rights Agreement] 
 24 

 EXHIBIT A 
 LIST OF PURCHASERS 
 Canaan VII L.P. 

See Company’s files for address 
 Hutton
Living Trust dated 12/10/96 
 See Company’s files for address 
 Safeguard Delaware, Inc. 
 See Company’s files for address 

Channel Medical Partners, L.P. 
 See
Company’s files for address 
 Red Abbey Venture Partners (QP), LP 
 See Company’s files for address 

 Red Abbey Venture Partners, LP 
 See Company’s files for address 
 Red Abbey CEO’s Fund, LP 

See Company’s files for address 
 Wheatley
New York Partners, L.P. 
 See Company’s files for address 
 Wheatley Partners III, L.P. 
 See Company’s files for address 

Wheatley Associates III, L.P. 
 See
Company’s files for address 

 Wheatley Foreign Partners III, L.P. 
 See Company’s files for address 
 Oliver D. Curme Children’s Trust 

See Company’s files for address 
 Edward R.
Gates and Liora L. Gates 
 See Company’s files for address 
 Walter Greenblatt & Associates, LLC 
 See Company’s files for address 

 EXHIBIT B 
 LIST OF JUNIOR HOLDERS 
 ABH Investors Limited Liability Company 

See Company’s files for address 

Dr. Howard Green 
 See Company’s files
for address 
 Dr. Walid Kuri-Harcuch 
 See Company’s files for address 
 Meytha Marsch de Kuri 

See Company’s files for address 
 Thomas V.
Hennessey 
 See Company’s files for address 
 JD Bernardy 
 See Company’s files for address 

Ed Gates, Esq. 
 See Company’s files for
address 
 Henry Lewis 
 See
Company’s files for address 

 Donald R. Kiepert, Jr. 
 See Company’s files for address 
 Peter B. Finn 

See Company’s files for address 
 Thomas
Kottler 
 See Company’s files for address 
 Dr. Federico Castro-Munozledo 
 See Company’s files for address 

Dr. David Dove 
 See Company’s files
for address 
 Dr. David Eisenbud 

See Company’s files for address 
 Salazar
Olivo 
 See Company’s files for address 
 Peter Fitzgerald, MD 
 See Company’s files for address 

Walter Greenblatt & Associates, LLC 

See Company’s files for address 
 Oceana
Partners 
 See Company’s files for address 

 Kevin Rakin 
 See Company’s files for addressForm of Director and Executive Officer Indemnification Agreement

 Exhibit 10.1 
 INDEMNIFICATION AGREEMENT 
 This Indemnification Agreement
(“Agreement”) is made as of [            ], 2011 by and between Advanced BioHealing, Inc., a Delaware corporation (the “Company”), and
[                                        ]
(“Indemnitee”). 
 RECITALS 

WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other capacities
unless they are provided with adequate protection through insurance and adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation; 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and
retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such
insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future
only at higher premiums and with more exclusions. At the same time, directors, officers and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to,
among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The certificate of incorporation and bylaws of the Company require indemnification of the officers and directors of the
Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (“DGCL”). The certificate of incorporation, bylaws and the DGCL expressly provide that the
indemnification provisions set forth therein are not exclusive and thereby contemplate that contracts may be entered into between the Company and members of the Board, officers and other persons with respect to indemnification; 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and
retaining such persons; 
 WHEREAS, the Board has determined that the increased difficulty in attracting and retaining
such persons is detrimental to the best interests of the Company’s stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future; 

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance
expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; 

WHEREAS, this Agreement is a supplement to and in furtherance of the certificate of incorporation and bylaws of the Company and
any resolutions adopted pursuant thereto and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and 
 WHEREAS, Indemnitee does not regard the protection available under the Company’s certificate of incorporation, bylaws and insurance as adequate in the present circumstances and may not be
willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve 

 
in such capacity. Indemnitee is willing to serve, to continue to serve and to take on additional service for or on behalf of the Company on the condition that he or she be so indemnified.

 NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do
hereby covenant and agree as follows: 
 1. Services to the Company. Indemnitee will serve or continue to serve as an
officer, director or key employee of the Company for so long as Indemnitee is duly elected or appointed or until Indemnitee tenders his or her resignation. 
 2. Definitions. As used in this Agreement: 
 (a) “Beneficial
Owner” shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the
stockholders of the Company approving a merger of the Company with another entity. 
 (b) A “Change in
Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events: 
 (i) Acquisition of Stock by Third Party. Any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the
combined voting power of the Company’s then outstanding securities; 
 (ii) Change in Board of
Directors. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals, who at the beginning of such period constitute the Board, and any new director (other than a
director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company’s
stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason
to constitute at least a majority of the members of the Board; 
 (iii) Corporate Transactions. The
effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation
continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the combined voting power of the voting securities of the surviving entity
outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity; 

(iv) Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an
agreement or series of agreements for the sale or disposition by the Company of all or substantially all of the Company’s assets; or 
 (v) Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item
on any similar schedule or form) promulgated under the Exchange Act, whether or not the Company is then subject to such reporting requirement. 

  
 2 

 (c) “Corporate Status” describes the status of a person who is or
was a director, officer, trustee, general partner, managing member, fiduciary, employee or agent of the Company or of any other Enterprise which such person is or was serving at the request of the Company. 

(d) “Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in
respect of which indemnification is sought by Indemnitee. 
 (e) “Enterprise” shall mean the Company and
any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, general partner,
managing member, fiduciary, employee or agent. 
 (f) “Exchange Act” shall mean the Securities Exchange
Act of 1934, as amended. 
 (g) “Expenses” shall include all reasonable attorneys’ fees, retainers,
court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses of the type customarily incurred
in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include expenses incurred in connection with any
appeal resulting from any Proceeding, including, without limitation, the premium, security for and other costs relating to any cost bond, supersedeas bond or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in
settlement by Indemnitee or the amount of judgments or fines against Indemnitee. 
 (h) “Independent
Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any
matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a
claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a
conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above
and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. 

(i) “Person” shall have the meaning set forth in Sections 13(d) and 14(d) of the Exchange Act; provided,
however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company and (iii) any corporation owned, directly or indirectly, by the
stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. 
 (j) The term
“Proceeding” shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, formal or informal, inquiry, administrative hearing or any other actual,
threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative or investigative nature, in which Indemnitee was, is or will be involved as a party, witness or otherwise
by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken (or failure to act) by him or her or of any action (or failure to act) on his or her part while acting as a director or officer of

  
 3 

 
the Company, or by reason of the fact that he or she is or was serving at the request of the Company as a director, officer, trustee, general partner, managing member, fiduciary, employee or
agent of any other Enterprise, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement or advancement of Expenses can be provided under this Agreement.

 (k) References to “other enterprise” shall include employee benefit plans; references to
“fines” shall include any excise tax assessed with respect to any employee benefit plan; references to “serving at the request of the Company” shall include any service as a director, officer, employee
or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he
or she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred
to in this Agreement. 
 3. Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee in accordance
with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant (as a witness or otherwise) in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in
its favor. Pursuant to this Section 3, Indemnitee shall be indemnified against all Expenses, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or
in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee
acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding, he or she had no reasonable cause to believe that his or her conduct was
unlawful. 
 4. Indemnity in Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee in
accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant (as a witness or otherwise) in any Proceeding by or in the right of the Company to procure a judgment in its favor.
Pursuant to this Section 4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee
acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to
which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that any court in which the Proceeding was brought or the Delaware Court of Chancery shall determine upon application that,
despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification. 
 5. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of this Agreement, to the extent that Indemnitee is a party to (or a participant
in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her
in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify
Indemnitee against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with each successfully resolved claim, issue or matter. If Indemnitee is not wholly successful in such Proceeding, the Company also
shall indemnify Indemnitee against all Expenses reasonably incurred in connection 

  
 4 

 
with a claim, issue or matter related to any claim, issue or matter on which Indemnitee was successful. For purposes of this Section and without limitation, the termination of any claim, issue or
matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. 
 6. Indemnification For Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a witness in any Proceeding
to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith. 

7. Additional Indemnification. 
 (a) Notwithstanding any limitation in Sections 3, 4 or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by law if Indemnitee is a party to or threatened to be made a party to any
Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or
payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection with the Proceeding. No indemnity shall be made under this
Section 7(a) on account of Indemnitee’s conduct which constitutes a breach of Indemnitee’s duty of loyalty to the Company or its stockholders or is an act or omission not in good faith or which involves intentional misconduct or a
knowing violation of the law. 
 (b) For purposes of Section 7(a), the meaning of the phrase “to the fullest
extent permitted by law” shall include, but not be limited to: 
 (i) the fullest extent permitted
by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement or the corresponding provision of any amendment to or replacement of the DGCL; and 

(ii) the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of
this Agreement that increase the extent to which a corporation may indemnify its officers and directors. 
 8. Exclusions.
Notwithstanding any other provision in this Agreement, the Company shall not be obligated under this Agreement to indemnify Indemnitee in connection with any claim made against Indemnitee: 

(a) for which payment has actually been received by or on behalf of Indemnitee under any insurance policy or other indemnity provision,
except with respect to any excess beyond the amount actually received under any insurance policy or other indemnity provision; [FOR DIRECTORS AFFILIATED WITH A VC FUND ONLY: provided that the foregoing shall not affect the
rights of Indemnitee or the Fund Indemnitors set forth in Section 14(c) below;] 
 (b) for an accounting of profits made
from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act or similar provisions of state statutory law or common law; or 

(c) except as otherwise provided in Sections 13(d)-(f) hereof, prior to a Change in Control, in connection with any Proceeding (or
any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or 

  
 5 

 
its directors, officers, employees or other indemnitees, unless (i) the Board of Directors of the Company authorized the Proceeding (or any part of any Proceeding) prior to its initiation or
(ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law. 
 9. Advances of Expenses; Defense of Claim. 
 (a) Notwithstanding any
provision of this Agreement to the contrary, the Company shall advance the Expenses incurred by Indemnitee in connection with any Proceeding within ten (10) days after the receipt by the Company of a statement or statements requesting such
advances from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s ability to repay the expenses and without regard to
Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement. Advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses
incurred preparing and forwarding statements to the Company to support the advances claimed. Indemnitee shall qualify for advances solely upon the execution and delivery to the Company of an undertaking providing that Indemnitee undertakes to repay
the advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. This Section 9(a) shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to
Section 8. 
 (b) The Company will be entitled to participate in the Proceeding at its own expense. 

(c) The Company shall not settle any action, claim or Proceeding (in whole or in part) which would impose any Expense, judgment, fine,
penalty or limitation on Indemnitee without Indemnitee’s prior written consent. 
 10. Procedure for Notification
and Application for Indemnification. 
 (a) Within sixty (60) days after the actual receipt by Indemnitee of notice
that he or she is a party to or a participant (as a witness or otherwise) in any Proceeding, Indemnitee shall submit to the Company a written notice identifying the Proceeding. The omission by Indemnitee to notify the Company will not relieve the
Company from any liability which it may have to Indemnitee (i) otherwise than under this Agreement and (ii) under this Agreement unless and only to the extent that the Company can establish that such omission to notify resulted in actual
prejudice to the Company. 
 (b) Indemnitee shall thereafter deliver to the Company a written application to indemnify
Indemnitee in accordance with this Agreement. Such application(s) may be delivered from time to time and at such time(s) as Indemnitee deems appropriate in his or her sole discretion. Following such a written application for indemnification by
Indemnitee, Indemnitee’s entitlement to indemnification shall be determined in accordance with Section 11(a) of this Agreement. 
 11. Procedure Upon Application for Indemnification. 
 (a) Upon
written request by Indemnitee for indemnification pursuant to Section 10(b), a determination, if required by applicable law, with respect to Indemnitee’s entitlement thereto shall be made in the specific case: (i) by a majority vote
of the Disinterested Directors, even if constituting less than a quorum of the Board; or (ii) if so requested by Indemnitee, in his or her sole discretion, by Independent Counsel in a written opinion to the Board, a copy of which shall be
delivered to Indemnitee. If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall reasonably cooperate with

  
 6 

 
the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable
advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including
attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to
indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. 
 (b) In the event the
determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 11(a) hereof, the Independent Counsel shall be selected as provided in this Section 11(b). If a Change in Control shall not have
occurred, the Independent Counsel shall be selected by the Board of Directors, and the Company shall give written notice to Indemnitee advising him of the identity of the Independent Counsel so selected and the basis for the Board determination that
such counsel qualified as Independent Counsel. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board of Directors, in which event
the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within 10 days
after such written notice of selection shall have been received, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the
ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such
assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and
until such objection is withdrawn or a court of competent jurisdiction has determined that such objection is without merit. If, within 20 days after submission by Indemnitee of a written request for indemnification pursuant to Section 10(b)
hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent jurisdiction (the “Court”) for resolution of any objection which shall have been
made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Court or by such other person as the Court shall designate, and the person with
respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 11(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 13(a) of this
Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). 

(c) The Company agrees to pay the reasonable fees of Independent Counsel and to fully indemnify such Independent Counsel against any and
all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. 

12. Presumptions and Effect of Certain Proceedings. 

(a) In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such
determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 10(b) of this Agreement, and the Company shall have the burden
of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including

  
 7 

 
by the Board or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because
Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by the Board or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or
create a presumption that Indemnitee has not met the applicable standard of conduct. 
 (b) If the person, persons or entity
empowered or selected under Section 11 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the
requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact
necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day
period shall be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time
for the obtaining or evaluating of documentation and/or information relating thereto. 
 (c) The termination of any Proceeding
or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely
affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to
any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful. 
 (d) For
purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied
to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or
by an appraiser or other expert selected by the Enterprise. The provisions of this Section 12(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed or found to have met the
applicable standard of conduct set forth in this Agreement. 
 (e) The knowledge and/or actions, or failure to act, of any other
director, trustee, partner, managing member, fiduciary, officer, agent, advisor or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. 

13. Remedies of Indemnitee. 
 (a) In the event that (i) a determination is made pursuant to Section 11 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of
Expenses is not timely made pursuant to Section 9 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 11(a) of this Agreement within the time period specified in
Section 12(b) of this Agreement, (iv) payment of indemnification is not made pursuant to Section 5, 6, 7 or the last sentence of Section 11(a) of this Agreement within ten (10) days after receipt by the Company of a written
request therefor or (v) payment of indemnification pursuant to Section 3 or Section 4 of this Agreement is not made within ten (10) days after a determination has been made that

  
 8 

 
Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by a court of his or her entitlement to such indemnification or advancement of Expenses. Alternatively,
Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. The Company shall not oppose Indemnitee’s right to
seek any such adjudication or award in arbitration. 
 (b) In the event that a determination shall have been made pursuant to
Section 11(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 13 shall be conducted in all respects as a de novo trial or
arbitration on the merits, and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 13, the Company shall have the burden of proving Indemnitee
is not entitled to indemnification or advancement of Expenses, as the case may be, and the Company may not refer to or introduce into evidence any determination pursuant to Section 11(a) of this Agreement adverse to Indemnitee for any purpose.
If Indemnitee commences a judicial proceeding or arbitration pursuant to this Section 13, Indemnitee shall not be required to reimburse the Company for any advances pursuant to Section 9 until a final determination is made with respect to
Indemnitee’s entitlement to indemnification (as to which all rights of appeal have been exhausted or lapsed). 
 (c) If a
determination shall have been made pursuant to Section 11(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this
Section 13, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification or
(ii) a prohibition of such indemnification under applicable law. 
 (d) In the event that Indemnitee, pursuant to this
Section 13, seeks a judicial adjudication of or an award in arbitration to enforce his or her rights under, or to recover damages for breach of, this Agreement, Indemnitee shall be entitled to recover from the Company, and shall be indemnified
by the Company against, any and all Expenses actually and reasonably incurred by him or her in such judicial adjudication or arbitration. If it shall be determined in said judicial adjudication or arbitration that Indemnitee is entitled to receive
part but not all of the indemnification or advancement of Expenses sought, Indemnitee shall be entitled to recover from the Company, and shall be indemnified by the Company against, any and all Expenses reasonably incurred by Indemnitee in
connection with such judicial adjudication or arbitration. 
 (e) The Company shall be precluded from asserting in any judicial
proceeding or arbitration commenced pursuant to this Section 13 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company
is bound by all the provisions of this Agreement. 
 (f) The Company shall indemnify Indemnitee to the fullest extent permitted
by law against all Expenses and, if requested by Indemnitee, shall (within ten (10) days after the Company’s receipt of such written request) advance such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any
judicial proceeding or arbitration brought by Indemnitee for (i) indemnification or advances of Expenses by the Company under this Agreement or any other agreement or provision of the Company’s certificate of incorporation or bylaws now or
hereafter in effect or (ii) recovery or advances under any insurance policy maintained by any person for the benefit of Indemnitee, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advance or
insurance recovery, as the case may be. 

  
 9 

 14. Non-exclusivity; Survival of Rights; Insurance; [FOR DIRECTORS AFFILIATED
WITH A VC FUND ONLY: Primacy of Indemnification;] Subrogation. 
 (a) The rights of indemnification and to
receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Company’s certificate of incorporation, the Company’s
bylaws, any agreement, a vote of stockholders, a resolution of directors or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of
any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. The parties hereto intend that, to the extent that a change in Delaware law, whether by statute or judicial decision, permits
greater indemnification or advancement of Expenses than would be afforded currently under the Company’s bylaws and this Agreement, the Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy
herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law, in equity or
otherwise. The assertion or employment of any right or remedy hereunder or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. 
 (b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, trustees, partners, managing members, fiduciaries, employees or agents
of the Company or of any other Enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any
such director, trustee, partner, managing member, fiduciary, officer, employee or agent under such policy or policies. If, at the time the Company receives notice from any source of a Proceeding as to which Indemnitee is a party or a participant (as
a witness or otherwise), the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company
shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. 

(c) [FOR DIRECTORS AFFILIATED WITH A VC FUND ONLY: The Company hereby acknowledges that Indemnitee has certain rights to
indemnification, advancement of expenses and/or insurance provided by [INSERT NAME OF VC ENTITY] and certain of its affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (i) that it is the
indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary),
(ii) that it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and
as required by the terms of this Agreement and the certificate of incorporation or bylaws of the Company (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and,
(iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees
that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of
contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of
the terms of this Section 14(c).] 

  
 10 

 [(d)] [FOR DIRECTORS AFFILIATED WITH A VC FUND ONLY: Except as provided in
paragraph (c) above,] [i]n the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee [FOR DIRECTORS AFFILIATED WITH A VC FUND ONLY:
(other than against the Fund Indemnitors)], who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 [(e)] [FOR DIRECTORS AFFILIATED WITH A VC FUND ONLY: Except as provided in paragraph (c) above,] [t]he
Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received such payment
under any insurance policy, contract, agreement or otherwise. 
 [(f)] [FOR DIRECTORS AFFILIATED WITH A VC FUND
ONLY: Except as provided in paragraph (c) above,] [t]he Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, trustee, partner,
managing member, fiduciary, employee or agent of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such Enterprise. 

15. Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after
the date that Indemnitee shall have ceased to serve as a director or officer of the Company or as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other corporation, partnership, joint venture, trust,
employee benefit plan or other enterprise which Indemnitee served at the request of the Company; or (b) one (1) year after the final termination of any Proceeding (including any rights of appeal thereto) then pending in respect of which
Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any Proceeding commenced by Indemnitee pursuant to Section 13 of this Agreement relating thereto (including any rights of appeal of any Section 13
Proceeding). 
 16. Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal
or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision
held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or
provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including,
without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent
manifested thereby. 
 17. Enforcement and Binding Effect. 

(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in
order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company. 

  
 11 

 (b) This Agreement constitutes the entire agreement between the parties hereto with respect
to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof. 

(c) The indemnification and advancement of expenses provided by or granted pursuant to this Agreement shall apply to Indemnitee’s
service as an officer, director or key employee of the Company prior to the date of this Agreement. 
 (d) The indemnification
and advancement of expenses provided by or granted pursuant to this Agreement shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such
a person. 
 18. Modification and Waiver. No supplement, modification or amendment of this Agreement shall be binding
unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.

 19. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any
summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the
Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise, except as provided in Section 10(a). 
 20. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (a) if delivered by hand and if
receipt is acknowledged in writing by the party to whom said notice or other communication shall have been directed or (b) if mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is
so mailed: 
 (a) If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as
Indemnitee shall provide in writing to the Company. 
 (b) If to the Company to: 

Advanced BioHealing, Inc. 
 [                                 
       ] 

[                      
                  ] 
 Attn.:
Secretary 
 or to any other address as may have been furnished to Indemnitee in writing by the Company. 

21. Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is
unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in
settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect:
(i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (ii) the relative fault of the Company

  
 12 

 
(and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s). 

22. Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and
construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 13(a) of this Agreement, the Company
and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the “Delaware
Court”) and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or
proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not a resident of the State of Delaware, irrevocably Corporation Service Company, 2711 Centerville Road, Suite 400, in the City of
Wilmington, County of New Castle, as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if
served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court and (v) waive and agree not to plead or to make any claim that any such
action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. 
 23. Identical
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by
the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement. 
 24.
Miscellaneous. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of the sections and paragraphs of this Agreement are inserted for convenience only and shall not be deemed to
constitute part of this Agreement or to affect the construction thereof. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

  
 13 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and
year first above written. 
  

									
	ADVANCED BIOHEALING, INC.,	 		 	INDEMNITEE
	a Delaware corporation	 		 		 	
				
	By:	 	  
	 		 	  

	Name:	 	  
	 		 	[NAME]
	Title:	 	  
	 		 		 	
					
		 		 		 	Address:	 	  

		 		 		 	  

		 		 		 	  

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}]]